#### **RESEARCH ARTICLE**

OPEN ACCESS OPEN ACCESS

### Severe postoperative complications after minimally invasive esophagectomy reduce the long-term prognosis of well-immunonutrition patients with locally advanced esophageal squamous cell carcinoma

Chao Chen<sup>a,b,c\*</sup>, Shao-Jun Xu<sup>a,b,c\*</sup>, Zhi-Fan Zhang<sup>a,b,c</sup>, Cheng-Xiong You<sup>a,b,c</sup>, Yun-Fan Luo<sup>a,b,c</sup>, Rui-Qin Chen<sup>a,b,c</sup> and Shu-Chen Chen<sup>a,b,c</sup>

<sup>a</sup>Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China; <sup>b</sup>Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China; <sup>c</sup>Fujian Provincial Key Laboratory of Cardiothoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

#### ABTRACT

**Background:** While severe postoperative complications (SPCs) impact cancer prognosis, their effect on locally advanced esophageal squamous cell carcinoma (ESCC) patients with varying immunonutritional statuses after minimally invasive esophagectomy (MIE) is unclear.

**Methods:** This retrospective study analyzed 442 patients with locally advanced ESCC who underwent MIE, investigating the relationship between SPCs and survival based on preoperative immunonutritional status, determined by the prognostic nutritional index (PNI). Nomograms were developed for patients with preserved immunonutritional status using Cox regression, and their performance was assessed.

**Results:** Of the patients, 102 (23.1%) experienced SPCs after MIE. Five-year overall survival (OS) and disease-free survival (DFS) were significantly different between SPCs and non-SPCs groups (p<0.001). In the preserved immunonutritional group, SPCs significantly reduced 5-year OS (p=0.008) and DFS (p=0.011), but not in the poor immunonutritional group (OS p=0.152, DFS p=0.098). Multivariate Cox regression identified SPCs as an independent risk factor for OS (HR = 1.653, p=0.013) and DFS (HR = 1.476, p=0.039). A nomogram for predicting OS and DFS in preserved immunonutritional patients demonstrated excellent performance.

**Conclusions:** SPCs significantly affect prognosis in ESCC patients with preserved immunonutritional status after MIE. Nomograms based on SPCs can predict OS and DFS in these patients.

#### **ARTICLE HISTORY**

Received 23 May 2024 Revised 17 August 2024 Accepted 19 August 2024

#### **KEYWORDS**

Minimally invasive esophagectomy; esophageal squamous cell carcinoma; severe postoperative complications; prognostic nutritional index

#### 1. Introduction

Esophageal carcinoma is the seventh most prevalent malignant neoplasm globally with the sixth highest number of cancer-related fatalities [1]. Esophageal cancer is an aggressive and highly malignant tumour with an early onset of lymph node metastasis. However, early esophageal cancer has atypical symptoms. As a result, most esophageal cancer patients with progressive dysphagia are often diagnosed in the middle or late stages, resulting in poor prognosis [2]. Besides, the 5-year postoperative survival rates of esophageal cancer patients are different among the groups (group based on the tumour-lymph node-metastasis (TNM) staging system, established by the American Joint Committee on Cancer (AJCC)). Specifically, the survival rates at stages IIa, IIb, III, and IV are 44.2%, 42.8%, 17.1%, and 13.2%, respectively [3,4].

Definitive surgical intervention combined with lymph node dissection has been widely used for the management of esophageal carcinoma. Besides, minimally invasive esophagectomy (MIE) has also been used for esophageal carcinoma treatment due to evolution of surgical techniques [5]. However, most esophageal cancer patients (50%) experience severe postoperative complications (SPCs) after minimally invasive procedures [6]. Besides increased treatment costs and prolonged hospitalization, SPCs influences the postoperative convalescence and quality of life of esophageal cancer resection recipients. SPCs also affect

CONTACT Shu-Chen Chen 🖾 cscdoctor@163.com 🗈 Department of Thoracic Surgery, Fujian Medical University Union Hospital, No.29 Xin quan Road, Fuzhou 350001, Fujian Province, China.

\*Chao Chen and Shao-Jun Xu have contributed equally to this work and should be considered as co-first authors.

© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.



Supplemental data for this article can be accessed online at https://doi.org/10.1080/07853890.2024.2440622.

the long-term survival prospects of esophageal cancer resection recipients [7].

Previous studies have found that SPCs have different effects on the prognosis of tumour patients under different immune and nutritional status [8-10]. A range of nutritional and immune markers, including the prognostic nutrition index (PNI), Glasgow prognostic score, and neutrophil-albumin ratio, can be used to identify prognostic survival in cancer patients [11–15]. PNI was initially defined by Buzby et al. and it encompasses multiple parameters [16]. PNI assesses the risk of postoperative complications based on a patient's initial nutritional status. The PNI is widely used to indicate immune-nutritional status. Notably, PNI is significantly correlated with treatment efficacy and long-term prognosis in various solid tumour types [17–19]. Esophageal squamous cell carcinoma (ESCC) is the dominant histopathological subtype of esophageal cancer in Asia, representing 90% of all cases [20]. Nevertheless, the impact of SPCs on the prognosis of locally advanced ESCC patients with distinct immune-nutritional statuses is unclear.

This study aimed to assess the preoperative immune-nutritional status of patients with locally advanced ESCC using the PNI and the effect of SPCs on the long-term prognosis of patients with varying immune-nutritional statuses after MIE.

#### 2. Materials and methods

### 2.1. Study populations and design

This retrospective analysis involved a continuous cohort of patients with locally advanced ESCC who had undergone MIE at the Fujian Medical University Affiliated Union Hospital from January 2011 to December 2018. Inclusion criteria were: (1) Patients with histologically-confirmed ESCC, (2) postoperative pathological stage II-III patients, (3) Patients who underwent MIE, and (4) Patients without concurrent malignancies. Exclusion criteria included: (1) Patients with postoperative pathological evidence of positive margins, (2) Patients whose intraoperative findings showed tumour metastasis, (3) Patients with incomplete clinical data or those lost to follow-up, (4) patients who changed to open surgery, and (5) individuals with severe cardiopulmonary insufficiency and could not tolerate surgery. Finally, 442 patients with locally advanced ESCC were enrolled in this study. The patients were divided into groups based on the presence or absence of SPCs. Clinical and pathological data, surgical details, and postoperative complications were also recorded. Pathological diagnoses and staging were performed following the 8th edition of the TNM staging system developed by the AJCC. This study followed the Helsinki Declaration protocols and was approved by the Institutional Review Board of Fujian Medical University Union Hospital (IRB number: 2021QH009). The requirement for written informed consent was waived by the ethics committee of Fujian Medical University Union Hospital because of the retrospective nature of the study.

#### 2.2. Definitions

The postoperative severe complications were classified based on the Clavien-Dindo grading system, where grade III and higher complications were regarded as Severe Postoperative Complications (SPCs). The Prognostic Nutritional Index (PNI) was determined as described by Onodera (the multiplication of the serum albumin level (g/100 ml) by 10 and the total peripheral lymphocyte count (10<sup>9</sup>/mm<sup>3</sup>) by 0.005) [8]. The patients were categorized into two groups, with the lower quartile Q1 as the truncation point (poor immune-nutritional group).

#### 2.3. Follow-up

Comprehensive outpatient follow-up assessments, including physical, blood biochemical, and imaging examinations, were scheduled 1, 3, and 6 months after the operation, followed by biannual reassessments for 2–3 years. The follow-ups were then conducted semi-annually for 5 years. Notably, follow-up was conducted *via* telephone or written communication for patients who could not attend outpatient follow-up evaluations.

#### 2.4. Outcome measures

The primary outcome of this study was to analyze the effect of SPC on the prognosis of ESCC patients in different immunonutritional states, and to evaluate independent risk factors affecting Overall Survival (OS) and Disease-Free Survival (DFS). The secondary outcome was to establish and internally validate a nomogram for predicting the prognosis of ESCC patients for clinical convenience.

### 2.5. Treatment protocols

All patients received a complete preoperative assessment after admission, including a detailed medical history and physical examination by the resident, and laboratory tests such as blood, urine, and stool. Gastroscopy, enhanced computed tomography of the neck, chest and upper abdomen and ultrasound of the neck, as well as cardiopulmonary function assessment. Patients are screened for nutrition before surgery, and those at risk of nutrition are given nutritional preparations by oral or enteral nutrition.

Patients with locally advanced esophageal cancer assessed as cT3-4a or N1-2 may be considered for preoperative neoadjuvant chemotherapy [21]. Neoadjuvant therapy is applied based on a comprehensive assessment of the patient's physical condition, doctor's evaluation, and patient's willingness. The neoadjuvant treatment options in this study include chemotherapy, radiotherapy, or a combination of both. According to the recommendations in the diagnosis and treatment guidelines for esophageal cancer, we recommend adjuvant therapy for pT4aN0M0/ postoperative PT1-4aN+M0 ESCC patients [22]. Postoperative adjuvant treatment is not mandatory, but is applied based on a comprehensive assessment of pathological findings, treatment preferences, physical condition, and physician assessment.

The surgical method, approach and procedure are determined by the surgeon. Lymph node dissection is mainly determined by the location of the tumour: if there is no suspicious enlarged lymph node in the neck, the middle and lower thoracic esophageal cancer is routinely treated with complete thoracic and abdominal two-field lymph node dissection. If there is suspicious enlarged lymph node in the neck and upper thoracic esophageal cancer, three-field lymph node dissection of the neck, chest and abdomen is performed.

After the operation, the patient is given fasting, continuous gastrointestinal decompression, total intravenous nutrition and other treatments. Intravenous nutrition is gradually reduced until intravenous nutrition is stopped. When it is confirmed that there is no anastomotic leakage and then a liquid diet is started and gradually transitioned to a semi-liquid diet.

#### 2.6. Statistical analysis

The OS was defined as the duration from the surgical intervention to the occurrence of death or the latest follow-up. The DFS was defined as the time from the surgical procedure to the emergence of tumour recurrence, metastasis, the ultimate follow-up visit, or death due to any cause.

 $\chi 2$  test or Fisher's exact test was used to analyze categorical variables, while the t-test or Mann-Whitney

U test was used for the analysis of continuous variables. Kaplan-Meier method was used to compare OS and DFS between groups. The disparities in survival were assessed via the Log-rank test. The factors influencing OS and DFS were evaluated through univariate and multivariate Cox proportional hazard regression, followed by the construction of nomograms based on the multifactorial outcomes. The performance of the predictive model was assessed through internal validation via 1000 iterations of the Bootstrap resampling technique, thereby generating calibration curves for model validation. The X-Tile software (Version 3.6.1) and an 'enumeration method', were used to determine the optimal cutoff values for survival risk scoring. The OS and DFS risk scores were grouped into three tiers: low risk, moderate risk, and high risk.

IBM SPSS Version 25.0 and R Version 3.5.1 were used for all statistical analyses. p < 0.05 was considered statistically significant level.

#### 3. Results

#### 3.1. Postoperative complications

About 23.1% (102 of 402 cases) of patients experienced SPCs postoperatively, including anastomotic leakage (n=70; 68.6%), pulmonary infections/pneumothorax (n=68; 66.7%), acute respiratory distress syndrome (n=10; 9.8%), postoperative hemorrhage (n=6 cases; 5.9%), chylothorax (n=9; 8.8%), and empyema (n=4; 3.9%) (Figure S1).

#### 3.2. Clinicopathological characteristics

In the study population, 94(21.3%) patients were older than 65 years, and 358 (81.0%) patients had no comorbidities. In addition, 62(14.0%) patients were assessed as high-risk malnutrition by MUST. In the included population, the majority of (69.9%) patients were male. There were 78(17.6%) patients receiving neoadjuvant therapy, 183 (41.4%) patients receiving postoperative adjuvant therapy, and 102(23.1%) patients developing SPCs after surgery (Table S1).

The pathological characteristics of the SPCs group and the non-SPCs group are presented in Table 1. The SPCs group had 102 patients (mean age;  $60\pm 8.1$  years), while the non-SPCs group comprised 340 patients (average age;  $59\pm 8.3$  years). Notably, compared with the SPCs group, the non-SPCs group had a higher proportion of female patients (p=0.008), higher ASA score (p<0.001), and lower tumour invasion (p=0.04). However, age (p=0.932), BMI (p=0.163), comorbidities (p=0.297), MUST (p=0.168), tumour location (p=0.902), histologic grade (p=0.188), lymph node metastasis (p=0.421), neoadjuvant therapy (p=0.374), surgical method (p=0.609), lymphadenectomy (p=0.135), intraoperatve blood loss (p=0.695), adjuvant therapy (p=0.958) and PNI (p=0.609) were not significantly different between the SPCs and non-SPCs groups.

# **3.3.** Relationship between SPCs and long-term outcome

Kaplan-Meier survival analysis revealed that the 5-year OS rates for the SPCs group and the non-SPCs group were 40.4% and 55.8%, respectively (p < 0.001), while the 5-year DFS rates were 32.1% and 52.5%, respectively (p < 0.001). Compared with the non-SPCs group,

Table 1. Correlations between SPCs and clinicopathological factors in patient with locally advanced ESCC.

Characteristics         Yein         102)         Noin-340)         P value           <65         8078.4%)         265(78.8%)         0.932           <65         8078.4%)         726(78.8%)         0.038           Sex         0.008         726(78.8%)         726(78.8%)           Sex         0.008         0.008           Female         20(19.6%)         213(33.2%)         0.038           Male         820(29.4%)         223(64.4%)         0.039           Sex         10.99.8%)         233(74.4%)         0.0297           Sex         10.99.8%)         233(74.4%)         0.297           Concolocitities         98.86.3%)         250(5.5%)         0.297           None         98.86.3%)         250(7.4%)         0.297           Hypertension         98.86.3%)         250(7.4%)         0.297           Morits         40.98.9%)         10.32.4%)         0.016           Coronary heart disease         11.0%)         30.9%)         0.297           Marits         87.67.7%)         223(80.3%)         0.001           Socor         30.5%)         20.011         0.016           Socor         30.5%)         20.021         0.016	-	SF		
Age(vars)0.922658078.4%)26078.8%)>652121.0%)72121.2%)Set72121.2%)0Fanale2019.0%)113(33.2%)Male82180.4%)22167.4.8%)BMI (kg/m)1112.1%)0185.585183.3%)2537.4.4%)185.585183.3%)2537.4.4%)185.585183.3%)2537.4.4%)185.585183.3%)2537.4.4%)185.585183.3%)2537.4.4%)185.7109.9%)0.297Name866.3%)27079.4%)Coronary Iterat Usease110.9%)0.297Name878.3%)2517.4.8%)0.297Name878.3%)2517.4.8%)0.297Name878.3%)2517.4.8%)0.168Must807.8%)2517.4.8%)0.168Must807.8%)2517.4.8%)0.001Inty risk2019.0%)2172.4.9%)0.001Inty risk2019.0%)2172.4.9%) <th>Characteristics</th> <th>Yes(n = 102)</th> <th>No(n= 340)</th> <th>P value</th>	Characteristics	Yes(n = 102)	No(n= 340)	P value
 > > Sef20210.4%)208(78.4%)208(78.5%)Sex0.008Fenale2019.6%)113(33.2%)Male2019.6%)227(66.5%)Male2019.6%)217(12.4%)Sex0.008.5%)217(12.4%)Sex0.008.5%)217(12.4%)Sex0.008.5%)217(12.4%)Sex0.008.5%)217(12.4%)Sex0.008.5%)217(12.4%)Sex0.009.5%)217(12.4%)Sex0.018.5%)217(12.4%)Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.029Sex0.029.7%0.021Sex0.029.7%0.021Sex0.029.7%0.021Sex0.029.7%0.021Sex0.029.7%0.021Sex0.0210.021Sex0.0210.021Sex0.0210.021Sex0.0210.021Sex0.0210.021Sex0.0210.021Sex0.0210.021Sex0.0210.021 <td>Age(years)</td> <td></td> <td></td> <td>0.932</td>	Age(years)			0.932
>>6520210.4%)7212.3%)	≤65	80(78.4%)	268(78.8%)	
Sex0.008Fenale2019.0%)13(33.2%)Male200.4%)227(65.8%)Male76.9%)431(12.1%)218.5-2585(83.3%)231(12.4%)2250.109.8%)41(12.1%)23685(83.3%)220(79.4%)247109.8%)501(15.5%)247109.8%)501(15.5%)247109.8%)501(15.5%)247100.9%100.9%248100.9%270(79.4%)249100.9%270(79.4%)249100.9%270(79.4%)249100.9%270(79.4%)249100.9%270(79.4%)249100.9%270(79.4%)249200.9%270(79.4%)249200.9%270(79.4%)2402019.0%270(70.4%)2402019.0%200(18.3%)2402019.0%200(18.3%)241210.5%200(18.3%)243210.2%200(27.4%)244210.2%200(18.3%)244210.2%200(18.3%)2452412.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)2452422.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)2462402.2%200(27.6%)	>65	22(21.6%)	72(21.2%)	
Fenale2019/0%)113(32.3%)Male82104.4%)227(56.8%)BMI (kgm/)(112.1%)18.5-2585(83.3%)223(74.4%)2.55109.8%)253(74.4%)Comorbidities109.8%)253(74.4%)None88(66.3%)270(79.4%)Male88(65.3%)300.9%)More98.8%)50(16.5%)Upbetes43.5%)113.2%)Conserpt heart disease11.0%)300.9%)More81.6%)273(80.3%)More81.6%)273(80.3%)More81.6%)273(80.3%)More81.6%)273(80.3%)Univ risk81.2%)2471(2.4%)High mark81.2%)2471(2.4%)High mark81.2%)2471(2.4%)Univ risk81.2%)2401.8%)More81.6%)212(2.4%)Univ risk81.2%)2411.4%)Univ risk81.2%)2411	Sex			0.008
Male BMI (kg/m)22/60/%)22/76/8%)36/36≤18.57/6.9%)411(2.1%)1≤18.58/58.3%)25/74.4%)2≥2510.08%)4613.5%)2.2Comorbidites0.2972None8/86.3%)2007.94%)2Pattering8/86.3%)2007.94%)2Coronary Isent disease110.8%30.9%)30.9%)MUST74/72.5%)23/80.3%)4011.8%Low risk8/7.8%)25/7.4%)30.9%)Medium risk807.8%)25/7.4%)30.9%)Medium risk2019.0%)4011.8%)30.0%Motion risk2019.6%)4011.8%)30.0%Migh risk2019.6%)4011.8%)30.0%Migh risk2019.6%)4011.8%)30.0%Migh risk2019.6%)3410.0%)30.0%Mid6664.7%)22162.4%)30.8%Mid6664.7%)22162.4%)30.8%Colo 1117.2%)31.7%30.8%G243.12.2%)44.12.2%)30.18G331.12.7%)46.13.5%)30.18G431.2%)30.8%30.4%G331.12.7%)30.18.5%)31.13.7%G331.12.7%)30.18.5%)31.13.7%G431.2%)30.18.5%)31.13.7%G431.2%)30.18.5%)31.13.7%G331.12.7%)30.18.5%)31.13.7%G431.2%)30.18.5%)31.13.7%G431.2%) <td>Female</td> <td>20(19.6%)</td> <td>113(33.2%)</td> <td></td>	Female	20(19.6%)	113(33.2%)	
BMI (kg/m)0.16318.5.27(6.9%)41(12.1%)18.5.2.585(83.3%)253(74.4%)2.5.710(9.8%)253(74.4%)Comorbidities8(86.3%)50(16.5%)None8(86.3%)50(16.5%)Hypertension9(8.8%)50(16.5%)Diabetes4(3.9%)11(3.2%)Coronary heart disease11.0%)3(0.9%)MUST273(80.3%)2019.6%)Kork8(86.3%)2019.6%)Mustik8(8.6%)221(2.4%)Tow risk8(8.6%)300(8.2%)Mustik8(8.6%)300(8.2%)Proximal6(64.7%)300(8.2%)Mide discover0.001Tomor location109.8%)44(10.0%)Proximal109.8%)44(10.0%)Mid66(64.7%)212(2.4%)Collogie grade0.04Tumor invasion0.04Til2(2.0%)3(18.5%)Til2(2.0%)3(18.5%)Til2(2.0%)3(18.5%)Til2(2.0%)3(18.5%)No3(3.5%)0.04Til2(2.0%)3(18.3%)Til2(2.0%)3(18.3%)Til2(2.0%)3(18.3%)Til2(2.0%)3(18.3%)Til2(2.0%)3(18.3%)Til2(2.0%)3(18.3%)Til3(3.6%)3(18.5%)Til3(3.6%)3(18.5%)Til3(3.6%)3(18.5%)Til3(3.6%)3(18.5%)Til3(3.6	Male	82(80.4%)	227(66.8%)	
\$18.5         7(6.9%)         41(12,1%)           225         10,98%)         25(74.4%)           225         10,98%)         6(15.5%)           225         0.098%)         55(16.5%)           None         88(86.3%)         27017.94%)           Papertension         98(86.3%)         30.9%)           Diabetes         4(3.9%)         31(3.7%)           Coronary heart disease         11(0.%)         30.9%)           MUST         74(72.5%)         23(80.3%)           Low risk         87(2.8%)         25(7.4%)           Medium risk         80(78.8%)         25(7.4%)           High risk         2019.6%)         42(12.4%)           Tumour focation         10(9.8%)         34(10.0%)           III/V         10(9.8%)         34(10.0%)         0.002           Mid         66(47.%)         12(16.2.4%)         14(16.1%)           Diatal         26(2.5.%)         34(10.0%)         0.018           G2         43(42.2%)         14(16.1%)         0.018           G2         43(42.4%)         12(16.2.4%)         0.148           Diatal         26(2.5.%)         34(10.0%)         0.04           G3         13(17.4%)         <	BMI (kg/m²)			0.163
18.5-2585(83.3%)253(74.4%)2-2510.98%)46(13.5%)Comoribidities0.297None9(8.8%)56(16.5%)Hypertonsion9(8.8%)11(3.2%)Coronary heart disease11.0%)30.9%)Coronary heart disease11.0%)23(3.0%)Worfs74(72.5%)23(8.0%)23(3.0%)Korisk87(8.3%)25(7.4%)23(3.0%)High risk87(8.3%)300(8.2%)<0.001	≤18.5	7(6.9%)	41(12.1%)	
≥25(90,8%)(47,79%)	18.5–25	85(83.3%)	253(74.4%)	
Comore0.0000.0000.0000.000Hypertension9(8.8%)56(16.5%)Hypertension9(8.8%)11(3.2%)Coronary heart disease(11.0%)30(9%)Coronary heart disease11(1.0%)25(3.3%)WUST25(3.7%)27(36.3%)0.068Medium risk87(78%)25(3.7%)0.001High risk20(19.6%)30(88.2%)<0.001	≥25	10(9.8%)	46(13.5%)	
None88(86.3%)270(79.4%)Hypertension98(86.3%)56(16.5%)Diabetes4(3.9%)113.2%)Coronary heart disease11(10%)13(0.9%)MUST0.68Low risk747.25%)275(80.3%)Medium risk80(7.8%)257(74%)High risk20(9.6%)42(12.4%)ASA score00(88.2%)<0.001	Comorbidities			0.297
Hypertension         98.8%)         5616.5%)           Diabetes         110.2%)         116.2%)           Coronary heart disease         110.9%)         2360.3%)           WST         0.668         0.68           Low risk         7472.5%)         2372.4%)         168           Medium risk         172.7%)         2572.4%)         0.001           High risk         2019.6%)         2012.4%)         0.001           SA score         0.001         0.001         0.001           Tumour location         0.020         0.001         0.001           Tumour location         0.020         0.001         0.001           Mid         66(64.7%)         21(26.24%)         0.001           Distal         0.202.5%)         94(10.0%)         0.018           G2 and score         0.188         0.018         0.018           G2 and score         0.188         0.018         0.018           G2 and score         0.018         0.018         0.018	None	88(86.3%)	270(79.4%)	
Diabetes         4(3.9%)         11(2.2%)           Coronary heart disease         1(1.9%)         3(0.9%)           MUST         0.168           Low risk         8(7.8%)         25(7.4%)           Medium risk         8(7.8%)         25(7.4%)           High risk         20(19.6%)         24(12.4%)           ASA score         0         0.001           III/W         37(3.63%)         40(11.8%)         <0.001	Hypertension	9(8.8%)	56(16.5%)	
Coronary heart disease(11.0%)(30.9%)MWST0.668Low risk7472.5%)2376.4%)High risk20(19.6%)42(12.4%)High risk20(19.6%)42(12.4%)KSA score0.00130.0088.2%)<0.001	Diabetes	4(3.9%)	11(3.2%)	
MUST         0.168           Low risk         974(72,5%)         237(80,3%)           Medium risk         87,8%)         257,74%)           High risk         2019,6%)         42(12,4%)           ASA score         3008,2%)         <0.001	Coronary heart disease	1(1.0%)	3(0.9%)	
Low risk74/72.5%)2373(0.3%)Heijn risk877.8%)257.4%)High risk201.6%)247.24%)High risk201.6%)300(88.2%)<0.001	MUST			0.168
Medium risk8/7.8%)2/57.4%)High risk20/19.6%)4/2(12.4%)ASA score300(88.2%)<0.001	Low risk	74(72.5%)	273(80.3%)	
High risk         2019.6%         42(12.4%)           SAS acore	Medium risk	8(7.8%)	25(7.4%)	
ASA scoreUIGS (63.7%)GO (08.2%)GO (01III/V3736.3%)40 (11.8%)40 (11.8%)00.01Tumour location0.98%)34 (10.0%)0.902Proximal09.8%)34 (10.0%)0.902Mid66 (64.7%)212 (62.4%)0.902Distal26 (25.5%)94 (27.6%)0.902Ga (2003)14 (12.0%)14 (12.5%)0.902Ga (2004)43 (42.9%)174 (51.2%)0.902Ga (2004)16 (15.7%)63 (18.5%)0.902Tumour invasion10 (15.7%)63 (18.5%)0.902Ta (2005)16 (15.7%)63 (18.5%)0.902Ta (2004)13 (13.0.4%)81 (23.8%)0.902Na (2005)10 (2005,3%)0.9020.902Na (2005)10 (10.5%)0.9020.902Na (200	High risk	20(19.6%)	42(12.4%)	
I/II65(63.7%)300(88.2%)<0.001III/V37(36.3%)40(11.8%)0.02Tumour location0.09.8%)34(10.0%)0.02Proximal109.8%)34(10.0%)0.02Distal0.66(64.7%)212(62.4%)0.02Distal0.66(64.7%)12(05.3%)0.02Constrained12(05.3%)0.020.02G243(42.2%)46(13.5%)0.02G313(12.7%)46(13.5%)0.02Tumour invasion0.040.020.02Ti/T da20.0%)63(18.5%)0.02Ti/T da16(15.7%)63(18.5%)0.02Lymph node metastasis0.420.020.02N037(36.3%)119(35.0%)0.02N120(05.3%)20(05.9%)0.02N231(30.4%)81(23.8%)0.02N365.9%)20(05.9%)0.02N081(79.4%)283(83.2%)0.02N081(79.4%)283(83.2%)0.03N081(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.4%)305(69.7%)0.05No81(79.5%) <td< td=""><td>ASA score</td><td></td><td></td><td></td></td<>	ASA score			
III/V37(36.3%)40(11.8%)Tumour location0.902Proximal10(9.8%)34(10.0%)Mid66(64.7%)212(62.4%)Distal26(25.5%)94(27.6%)Gast26(25.5%)94(27.6%)Gast26(25.5%)120(53.3%)Gast120(35.3%)174(51.2%)Gast120(35.3%)174(51.2%)Gast120(35.3%)100.8%%)Gast120(35.3%)100.8%%)Timour invasion0.8181.5%)Ta/Ta'16(15.7%)63(18.5%)Ta/Ta'37(36.3%)119(35.0%)Ta/Ta'37(36.3%)119(35.0%)No37(36.3%)120(35.3%)Na6(5.9%)20(5.9%)Na28(27.5%)120(35.3%)Na6(5.9%)20(5.9%)Na31(30.4%)81(32.8%)Na6(5.9%)20(5.9%)Na21(20.6%)57(16.8%)Na21(20.6%)57(16.8%)Na306(90.0%)100Na30(10.3%)100Na305(89.7%)100Na6(5.9%)306(90.0%)Na305(89.7%)100Na305(89.7%)305(89.7%)Na6(15.7%)30(10.3%)Na6(15.7%)30(10.3%)Na6(15.7%)30(10.3%)Na6(15.7%)30(10.3%)Na6(15.7%)30(10.3%)Na6(15.7%)30(10.3%)Na6(15.7%)30(10.3%)Na <td>1/11</td> <td>65(63.7%)</td> <td>300(88.2%)</td> <td>&lt;0.001</td>	1/11	65(63.7%)	300(88.2%)	<0.001
Tumour location0.902Proximal10(9.8%)34(10.0%)Proximal66(64.7%)32(10.24.%)Distal26(25.5%)94(27.6%)Controlling grade0.188GX/G146(45.1%)120(35.3%)G243(42.2%)174(51.2%)G313(12.7%)46(13.5%)G313(12.7%)63(18.5%)Tumour invasion0.068.8%)0.068.8%)T12(2.0%)30(8.8%)T2/4a8(42.4%)24/712.6%)Lymph node metastasis0.421N037(36.3%)119(35.0%)N231(30.4%)81(23.8%)N231(30.4%)81(23.8%)N231(30.4%)81(23.8%)N231(30.4%)81(33.6%)N221(20.6%)57(16.8%)N221(20.6%)57(16.8%)N366(9.3%)20(53.3%)N421(20.6%)57(16.8%)N366(9.3%)20(35.3%)N421(20.6%)57(16.8%)N366(9.3%)20(35.3%)N421(20.6%)57(16.8%)N421(20.6%)36(10.0%)N412(11.8%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)N412(11.6%)31(10.0%)	III/IV	37(36.3%)	40(11.8%)	
Proximal10(9.8%)34(10.0%)Mid66(64.7%)212(62.4%)Distal26(25.5%)212(62.4%)Histologic grade26(25.5%)120(35.3%)Gx/G143(42.2%)174(51.2%)G313(12.7%)46(13.5%)G313(12.7%)30(8.8%)Tumour invasion0.8T3/Ta2(2.0%)30(8.8%)T3/Ta16(15.7%)63(18.5%)T3/Ta16(15.7%)63(18.5%)T3/Ta16(15.7%)63(18.5%)T3/Ta24(27.5%)120(35.3%)No37(36.3%)119(35.0%)N128(27.5%)20(5.9%)N231(30.4%)81(23.3%)N231(30.4%)81(23.3%)N231(30.4%)28(83.2%)No65.9%/20(5.9%)No10(7.9%)28(83.2%)No12(12.6%)57(16.8%)No12(13.5%)30(80.0%)No12(13.6%)30(80.9%)No12(13.6%)30(80.9%)No12(11.8%)30(80.9%)No12(11.8%)30(80.9%)No12(11.8%)30(80.7%)Inter-field16(15.7%)35(10.3%)Inter-field16(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)32(10.2%)20016(15.7%)35(10.3%)20016(15.7%)32(10.2%)20016(15.	Tumour location			0.902
Mid       66(64,7%)       212(62.4%)         Distal       26(25.5%)       94(27.6%)         Distol       20(35.3%)       0.188         Gx/G1       46(45.1%)       120(35.3%)       0.168         G2       43(42.2%)       174(51.2%)       0.168         G3       13(12.7%)       46(13.5%)       0.17         Tumor invasion       2(2.0%)       30(8.8%)       0.17         T1       2(2.0%)       63(8.5%)       0.16         T2       16(15.7%)       63(18.5%)       0.421         T4       2(2.0%)       63(8.3%)       0.17         T4       2(2.0%)       63(18.5%)       0.421         T4       2(2.0%)       63(18.5%)       0.421         N0       37(36.3%)       119(35.0%)       0.120(35.3%)       0.11         N1       28(27.5%)       20(35.3%)       0.11       0.135         N2       31(30.4%)       81(23.8%)       0.11       0.136         N3       6(5.9%)       20(5.9%)       0.11       0.136       0.11         N4       28(27.5%)       31(30.4%)       81(33.8%)       0.11       0.13       0.11       0.13       0.11       0.11       0.11       0.11<	Proximal	10(9.8%)	34(10.0%)	
Distal26(25.5%)94(27.6%)Histologic grade0.188Gx/G146(45.1%)120(35.3%)G243(42.2%)174(51.2%)G313(12.7%)46(13.5%)Tumour invasion0.04T12(2.0%)30(8.8%)T2/T216(15.7%)63(18.5%)T3/T4a84(82.4%)247(72.6%)Lymph node metastasis0.421N028(27.5%)19(35.3%)N128(27.5%)10(35.3%)N231(30.4%)81(23.8%)N36(5.9%)20(5.9%)N421(20.6%)23(83.2%)N36(5.9%)23(83.2%)N412(11.8%)34(10.0%)No feed8(84.3%)35(89.7%)Nor Lewis12(11.8%)34(10.0%)Nor Lewis12(11.8%)35(10.3%)Nor Lewis12(11.8%)35(10.3%)Nor Lewis12(11.8%)35(10.3%)Nor Lewis12(11.8%)35(10.3%)Nor Lewis12(11.8%)35(10.3%)100-20038(37.3%)120(35.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)20016(15.7%)120(35.3%)200 <td< td=""><td>Mid</td><td>66(64.7%)</td><td>212(62.4%)</td><td></td></td<>	Mid	66(64.7%)	212(62.4%)	
Histologic grade0.188Gx/G146(13-1%)120(35.3%)G243(42.2%)174(51.2%)G313(12.7%)46(13.5%)G313(12.7%)46(13.5%)Tumour invasion2(2.0%)30(8.8%)T216(15.7%)63(18.5%)T3/T4a84(82.4%)247(72.6%)Lymph node metastasis0.421N037(36.3%)119(35.0%)N12(2.7%)120(53.3%)N231(30.4%)81(23.8%)N231(30.4%)81(23.8%)N36(5.9%)20(5.9%)N428(27.5%)0.609No81(79.4%)283(83.2%)Surgical method6(8.3%)30(600.0%)No81(79.4%)34(10.0%)Lymphadenectomy0.699McKeown90(88.2%)35(10.3%)Two-field16(15.7%)35(10.3%)Three-field16(15.7%)35(10.3%)Three-field16(15.7%)35(10.3%)100-20038(37.3%)120(35.3%)≥20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(15.7%)35(10.3%)20016(	Distal	26(25.5%)	94(27.6%)	
Gx/G1       46(45.1%)       120(35.3%)         G2       43(42.2%)       174(51.2%)         G3       13(12.7%)       46(13.5%)         Tumour invasion       0.04         T1       2(2.0%)       30(8.8%)         T2       16(15.7%)       63(18.5%)         T3/Tala       84(82.4%)       247(72.6%)         Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         N4       28(27.5%)       120(35.3%)         N3       6(5.9%)       20(5.9%)         N4       81(70.4%)       81(70.4%)         N4       81(79.4%)       28(38.2%)         N4       81(79.4%)       283(83.2%)         Surgical method       0.609         Nor Lewis       12(11.8%)       34(10.0%)         Lymphadenectomy       0.813(33.3%)       120(35.3%)         Three-field       16(15.7%)       35(10.3%)         100-200       38(37.3%)       120(35.3%)       120(35.3%)         2200       16(15.7%)       45(13.2%)       4	Histologic grade			0.188
G2       43(42.2%)       174(51.2%)         G3       13(12.7%)       46(13.5%)         G3       13(12.7%)       46(13.5%)         G3       2(2.0%)       30(8.8%)         T2       16(15.7%)       63(18.5%)         T3/74a       48(82.4%)       247(72.6%)         Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N2       13(0.4%)       81(23.8%)         N2       31(30.4%)       81(23.8%)         N2       31(30.4%)       81(23.8%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         N4       21(20.6%)       57(16.8%)         N3       0       51(13.8%)         N4       21(20.6%)       57(16.8%)         N4       112(1.8%)       24(10.0%)         N4       112(1.8%)       306(90.0%)         N4       112(1.8%)       306(90.0%)         N4       112(1.8%)       306(90.0%)         N4       112(1.8%)       305(89.7%)         N4       112(1.8%)       305(89.7%)         N4       112(1.8%)       305(89.7%)         N4       12(1.8%	Gx/G1	46(45.1%)	120(35.3%)	
G3       13(12.7%)       46(13.5%)         Tumour invasion       0.04         T1       2(2.0%)       30(8.8%)         T2       16(15.7%)       63(18.5%)         T3/T4a       48(2.4%)       24/72.6%)         Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         N4       6(5.9%)       20(5.9%)         No       81(79.4%)       283(83.2%)         No       81(79.4%)       283(83.2%)         Surgical method       9(88.2%)       306(90.0%)         Nor Lewis       12(1.1%)       281(1.3%)         Three-field       16(15.7%)       31(10.3%)         Three-field       16(15.7%)       35(10.3%)         Three-field       16(15.7%)       35(10.3%)         100-200       38(37.3%)       120(35.3%)         2200       16(15.7%)       35(13.2%)         No       60(58.8%)       199(58.5%)         No       60(58.8%)       199(58.5%)         No       60(58.8%)       199(58.5%)	G2	43(42.2%)	174(51.2%)	
Tumour invasion         0.04           T1         2(2.0%)         30(8.8%)           T2         16(15.7%)         63(18.5%)           T3/T4a         84(82.4%)         247(72.6%)           Lymph node metastasis         0.421           N0         37(36.3%)         119(35.0%)           N1         28(27.5%)         120(35.3%)           N2         31(30.4%)         81(23.8%)           N3         6(5.9%)         20(5.9%)           N4         28(27.5%)         20(5.9%)           N3         6(5.9%)         20(5.9%)           N3         6(5.9%)         20(5.9%)           Surgical method         81(79.4%)         283(83.2%)           No         81(79.4%)         283(83.2%)           Surgical method         90(88.2%)         306(90.0%)           Vor Lewis         12(11.8%)         30(690.0%)           Lymphadenectomy         0.135           Two-field         86(84.3%)         305(89.7%)           Three-field         16(15.7%)         35(10.3%)           100-200         38(37.3%)         120(35.3%)           2200         16(15.7%)         45(13.2%)           No         605(58.8%)         199(58.5%) <td>G3</td> <td>13(12.7%)</td> <td>46(13.5%)</td> <td></td>	G3	13(12.7%)	46(13.5%)	
T1       2(2.0%)       30(8.8%)         T2       16(15.7%)       63(18.5%)         T3/Tda       84(82.4%)       247(72.6%)         Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         N4       28(27.5%)       20(5.9%)         N3       6(5.9%)       20(5.9%)         N4       28(27.5%)       20(5.9%)         N4       28(27.5%)       20(3.3%)         N3       6(5.9%)       20(5.9%)         N4       28(27.9%)       283(83.2%)         N4       81(79.4%)       283(83.2%)         N4       20(5.9%)       20(5.9%)         Vor Lewis       12(11.8%)       36(69.0%)         Vor Lewis       12(11.8%)       35(89.7%)         Intraoperative blood loss(ml)       6.059       6.059         ≤100       48(7.1%)       175(51.5%)       6.059         100-200       48(7.3%)       120(3.53%)       2.053.3%)         ≥200       16(15.7%)       120(3.53.9%)       2.053.3%)         N	Tumour invasion			0.04
T2       16(15.7%)       63(18.5%)         T3/T4a       84(82.4%)       247(72.6%)         Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         N3       6(5.9%)       20(5.9%)         No       81(79.4%)       283(82.9%)         No       81(79.4%)       283(82.9%)         No       81(79.4%)       306(90.0%)         No       81(79.4%)       33(10.0%)         Vers Lewis       12(11.8%)       305(89.7%)         McKeown       90(88.2%)       305(89.7%)         Nor Lewis       12(11.8%)       35(10.3%)         Lymphadenectomy       0.035       100.695         Two-field       86(84.3%)       305(89.7%)         Intraoperatve blood loss(m)       15(15.7%)       200         ≤100       48(47.1%)       175(51.5%)         100-200       38(37.3%)       120(35.3%)         ≥200       16(15.7%)       45(13.2%)         No       60(58.8%)       199(58.5%)         Yes       42(41.2%)	T1	2(2.0%)	30(8.8%)	
T3/T4a       84(82.4%) $247(72.6\%)$ Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.5%)         N4       28(27.5%)       20(5.9%)         N3       6(5.9%)       20(5.9%)         N4       81(23.8%)       3         N4       81(23.8%)       3         N4       6(5.9%)       20(5.9%)         N4       81(79.4%)       81(23.8%)         N5       212(10.6%)       57(16.8%)       3         N4       81(79.4%)       233(83.2%)       3         N4       81(79.4%)       336(90.0%)       3         N5       306(90.0%)       306(90.0%)       3         V5       10(11.8%)       34(10.0%)       3         N5       305(89.7%)       305(89.7%)       3         Three-field       16(15.7%)       35(10.3%)       3         100-200       38(37.3%)       120(35.3%)       3         200       16(15.7%)       45(13.2%)       9         N6       60(58.8%)	Т2	16(15.7%)	63(18.5%)	
Lymph node metastasis       0.421         N0       37(36.3%)       119(35.0%)         N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         N4       28(27.5%)       20(5.9%)         N3       6(5.9%)       20(5.9%)         N4       21(20.6%)       20(5.9%)         N0       81(79.4%)       283(83.2%)         Surgical method       9(88.2%)       306(90.0%)         Nor Lewis       111.8%)       34(10.0%)         Lymphadenectomy       0.135         Two-field       86(84.3%)       305(89.7%)         Three-field       16(15.7%)       35(10.3%)         Intraoperative blood loss(ml)       0.695         2100       48(47.1%)       175(51.5%)         100-200       38(37.3%)       120(35.3%)         2200       16(15.7%)       45(13.2%)         200       16(15.7%)       9(58.5%)         Yes       42(41.2%)       141(41.5%)         PNI       0.695       55(74.1%)         Yes       29(28.4%)       88(25.9%)	T3/T4a	84(82.4%)	247(72.6%)	
No $37(36.3\%)$ $119(35.0\%)$ N1 $28(27.5\%)$ $120(35.3\%)$ N2 $31(30.4\%)$ $81(23.8\%)$ N3 $6(5.9\%)$ $20(5.9\%)$ Neoadjuvant therapy0.374Yes $21(20.6\%)$ $20(5.9\%)$ No $81(23.8\%)$ $0.374$ Surgical method $57(16.8\%)$ $0.609$ McKeown $90(88.2\%)$ $306(90.0\%)$ Ivor Lewis $2(11.8\%)$ $306(90.0\%)$ Lymphadenectomy $0(88.2\%)$ $306(90.0\%)$ Two-field $86(84.3\%)$ $305(89.7\%)$ Ihraoperatve blood loss(ml) $0.135$ Intraoperatve blood loss(ml) $0.609$ $200$ $8(37.3\%)$ $120(35.3\%)$ $200$ $16(15.7\%)$ $120(35.3\%)$ $200$ $16(15.7\%)$ $0.958$ No $0058.8\%$ $199(58.5\%)$ Yes $42(41.2\%)$ $141(41.5\%)$ PNI $0.609$ $247.1$ $73(71.6\%)$ $52(74.1\%)$ $247.1$ $29(28.4\%)$ $88(25.9\%)$	Lymph node metastasis			0.421
N1       28(27.5%)       120(35.3%)         N2       31(30.4%)       81(23.8%)         N3       6(5.9%)       20(5.9%)         Neoadjuvant therapy       0.374         Yes       21(20.6%)       57(16.8%)         No       81(79.4%)       283(83.2%)         Surgical method       0.609         McKeown       90(88.2%)       306(90.0%)         No       81(21.18%)       34(10.0%)         Lymphadenectomy       0.135         Two-field       86(84.3%)       305(89.7%)         Three-field       16(15.7%)       35(10.3%)         ≤100       48(47.1%)       175(51.5%)         100-200       38(37.3%)       120(35.3%)         ≥200       16(15.7%)       9         Adjuvant therapy       0.958         No       60(58.8%)       199(58.5%)         Yes       42(41.2%)       141(41.5%)         PNI       0.609         ≤47.1       29(28.4%)       88(25.9%)	NO	37(36.3%)	119(35.0%)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	N1	28(27.5%)	120(35.3%)	
N3 $6(5.9\%)$ $20(5.9\%)$ Neoadjuvant therapy       0.374         Yes $21(20.6\%)$ $57(16.8\%)$ No $21(20.6\%)$ $283(83.2\%)$ No $81(79.4\%)$ $283(83.2\%)$ Surgical method $0.609$ McKeown $90(88.2\%)$ $306(90.0\%)$ Ivor Lewis $12(11.8\%)$ $34(10.0\%)$ Lymphadenectomy $0.135$ Two-field $6(84.3\%)$ $305(89.7\%)$ Intraoperatve blood loss(ml) $0.695$ ≤100 $48(47.1\%)$ $35(10.3\%)$ $100-200$ $38(37.3\%)$ $120(35.3\%)$ ≥200 $48(47.1\%)$ $95(85.5\%)$ No $60(58.8\%)$ $199(58.5\%)$ Yes $42(41.2\%)$ $141(41.5\%)$ PNI $0.609$ $≤47.1$ $29(28.4\%)$ $88(25.9\%)$	N2	31(30.4%)	81(23.8%)	
Neoadjuvant therapy       0.374         Yes       21(20.6%)       57(16.8%)         No       81(79.4%)       283(83.2%)         Surgical method       0.609         McKeown       90(88.2%)       306(90.0%)         Ivor Lewis       12(11.8%)       34(10.0%)         Lymphadenectomy       0.135         Two-field       86(84.3%)       305(89.7%)         Three-field       16(15.7%)       35(10.3%)         Intraoperatve blood loss(ml)       0.695         ≤100       48(47.1%)       175(51.5%)         100-200       38(37.3%)       120(35.3%)         ≥200       16(15.7%)       45(13.2%)         Mo       60(58.8%)       199(58.5%)         Yes       42(41.2%)       14(41.5%)         PNI       0.609         ≥47.1       73(71.6%)       252(74.1%)	N3	6(5.9%)	20(5.9%)	
Yes $21(20.6\%)$ $57(16.8\%)$ No $81(79.4\%)$ $283(83.2\%)$ Surgical method $0.609$ McKeown $90(88.2\%)$ $306(90.0\%)$ Ivor Lewis $12(11.8\%)$ $34(10.0\%)$ Lymphadenectomy $0.135$ Two-field $86(84.3\%)$ $305(89.7\%)$ Three-field $16(15.7\%)$ $35(10.3\%)$ Intraoperatve blood loss(ml) $0.695$ $\leq 100$ $48(47.1\%)$ $175(51.5\%)$ $100-200$ $38(37.3\%)$ $120(35.3\%)$ $\geq 200$ $16(15.7\%)$ $45(13.2\%)$ Adjuvant therapy $0.958$ No $60(58.8\%)$ $199(58.5\%)$ Yes $42(41.2\%)$ $141(41.5\%)$ PNI $0.609$ $\geq 47.1$ $73(71.6\%)$ $252(74.1\%)$ $<47.1$ $29(28.4\%)$ $88(25.9\%)$	Neoadjuvant therapy			0.374
No $81(79.4\%)$ $283(83.2\%)$ Surgical method       0.609         McKeown $90(88.2\%)$ $306(90.0\%)$ Ivor Lewis $12(11.8\%)$ $34(10.0\%)$ Lymphadenectomy       0.135         Two-field $86(84.3\%)$ $305(89.7\%)$ Three-field $16(15.7\%)$ $0.695$ Intraoperatve blood loss(ml) $0.695$ ≤100 $48(47.1\%)$ $175(51.5\%)$ $0.695$ 100-200 $38(37.3\%)$ $120(35.3\%)$ $2200$ $0.695$ $200$ $16(15.7\%)$ $45(13.2\%)$ $0.958$ No $60(58.8\%)$ $199(58.5\%)$ $0.958$ No $60(58.8\%)$ $199(58.5\%)$ $0.609$ Yes $42(41.2\%)$ $141(41.5\%)$ $0.609$ PNI $0.609$ $0.609$ $0.609$ $447.1$ $73(71.6\%)$ $252(74.1\%)$ $0.609$	Yes	21(20.6%)	57(16.8%)	
Surgical method0.609McKeown90(88.2%)306(90.0%)Ivor Lewis12(11.8%)34(10.0%)Lymphadenectomy0.135Two-field86(84.3%)305(89.7%)Three-field16(15.7%)0Intraoperatve blood loss(ml)0.695≤10048(47.1%)175(51.5%)100-20038(37.3%)120(35.3%)≥20016(15.7%)0.695Adjuvant therapy0.958No60(58.8%)199(58.5%)Yes42(41.2%)141(41.5%)PNI0.609≥47.173(71.6%)252(74.1%)<47.1	No	81(79.4%)	283(83.2%)	
Mckeown         90(88.2%)         306(90.0%)           Ivor Lewis         12(11.8%)         34(10.0%)           Lymphadenectomy         0.135           Two-field         86(84.3%)         305(89.7%)           Three-field         16(15.7%)         0.695           Intraoperatve blood loss(ml)         0.695           ≤100         48(47.1%)         175(51.5%)           100-200         38(37.3%)         120(35.3%)           ≥200         16(15.7%)         0.958           Mok         60(58.8%)         199(58.5%)           ≥200         60(58.8%)         199(58.5%)           Yes         42(41.2%)         141(5%)           PNI         0.609           ≤47.1         73(71.6%)         252(74.1%)	Surgical method			0.609
$\begin{array}{llllllllllllllllllllllllllllllllllll$	McKeown	90(88.2%)	306(90.0%)	
Lymphadenectomy0.135Two-field86(84.3%) $305(89.7\%)$ Three-field16(15.7%) $35(10.3\%)$ Intraoperatve blood loss(ml)0.695≤10048(47.1%)175(51.5%)100-20038(37.3%)120(35.3%)≥20016(15.7%)45(13.2%)≥20060(58.8%)199(58.5%)No60(58.8%)199(58.5%)Yes42(41.2%)141(41.5%)PNI0.609≥47.173(71.6%)252(74.1%)<47.1	Ivor Lewis	12(11.8%)	34(10.0%)	
Two-field86(84.3%) $305(89.7\%)$ Three-field16(15.7%) $35(10.3\%)$ Intraoperatve blood loss(ml)0.695≤10048(47.1%)175(51.5%)100-20038(37.3%)120(35.3%)≥20016(15.7%)45(13.2%)∠20060(58.8%)199(58.5%)No60(58.8%)199(58.5%)Yes42(41.2%)141(41.5%)PNI0.609≥47.173(71.6%)252(74.1%)<47.1	Lymphadenectomy			0.135
Three-field16(15.7%) $35(10.3\%)$ Intraoperatve blood loss(ml)0.695≤10048(47.1%)175(51.5%)100-20038(37.3%)120(35.3%)≥20016(15.7%)45(13.2%)Adjuvant therapy0.958No60(58.8%)199(58.5%)Yes42(41.2%)141(41.5%)PNI0.609≥47.173(71.6%)252(74.1%)<47.1	Two-field	86(84.3%)	305(89.7%)	
$ \begin{array}{c c c c c c } Intraoperatve blood loss(ml) & 0.695 \\ \leq 100 & 48(47.1\%) & 175(51.5\%) \\ 100-200 & 38(37.3\%) & 120(35.3\%) \\ \geq 200 & 16(15.7\%) & 45(13.2\%) \\ \hline \mbox{Adjuvant therapy} & 0.958 \\ No & 60(58.8\%) & 199(58.5\%) \\ Yes & 42(41.2\%) & 141(41.5\%) \\ Yes & 42(41.2\%) & 0.609 \\ \hline \mbox{PNI} & 0.609 \\ \geq 47.1 & 73(71.6\%) & 252(74.1\%) \\ < 47.1 & 29(28.4\%) & 88(25.9\%) \\ \end{array} $	Three-field	16(15.7%)	35(10.3%)	
	Intraoperatve blood loss(ml)			0.695
$\begin{array}{cccc} 100-200 & 38(37.3\%) & 120(35.3\%) \\ \ge 200 & 16(15.7\%) & 45(13.2\%) \\ \hline \mbox{Adjuvant therapy} & & 0.958 \\ No & 60(58.8\%) & 199(58.5\%) \\ Yes & 42(41.2\%) & 141(41.5\%) \\ \hline \mbox{PNI} & & 0.609 \\ \ge 47.1 & 73(71.6\%) & 252(74.1\%) \\ < 47.1 & 29(28.4\%) & 88(25.9\%) \end{array}$	≤100	48(47.1%)	175(51.5%)	
$\begin{array}{cccc} \ge 200 & 16(15.7\%) & 45(13.2\%) \\ \hline \mbox{Adjuvant therapy} & & & & & & & & & \\ No & 60(58.8\%) & 199(58.5\%) & & & & & & & \\ Yes & 42(41.2\%) & 141(41.5\%) & & & & & & & \\ PNI & & & & & & & & & & & & & \\ \ge 47.1 & 73(71.6\%) & 252(74.1\%) & & & & & & & & & & & & \\ \ge 47.1 & 29(28.4\%) & 88(25.9\%) & & & & & & & & & & & & & & \\ \end{array}$	100–200	38(37.3%)	120(35.3%)	
Adjuvant therapy $0.958$ No $60(58.8\%)$ $199(58.5\%)$ Yes $42(41.2\%)$ $141(41.5\%)$ PNI $0.609$ $\geq 47.1$ $73(71.6\%)$ $252(74.1\%)$ $< 47.1$ $29(28.4\%)$ $88(25.9\%)$	≥200	16(15.7%)	45(13.2%)	
No $60(58.8\%)$ $199(58.5\%)$ Yes $42(41.2\%)$ $141(41.5\%)$ PNI0.609 $\geq 47.1$ $73(71.6\%)$ $252(74.1\%)$ $<47.1$ $29(28.4\%)$ $88(25.9\%)$	Adjuvant therapy	· · ·	· · ·	0.958
Yes         42(41.2%)         141(41.5%)           PNI         0.609           ≥47.1         73(71.6%)         252(74.1%)           <47.1	No	60(58.8%)	199(58.5%)	
PNI         0.609           ≥47.1         73(71.6%)         252(74.1%)           <47.1	Yes	42(41.2%)	141(41.5%)	
≥47.1 73(71.6%) 252(74.1%) <47.1 29(28.4%) 88(25.9%)	PNI	• • • •		0.609
<47.1 29(28.4%) 88(25.9%)	≥47.1	73(71.6%)	252(74.1%)	
	<47.1	29(28.4%)	88(25.9%)	

the 5-year OS (p=0.0019) and DFS (p=0.0019) were significantly reduced in the SPCs group (Figure 1). These findings indicate that SPCs is a key predictive factor for patients with locally progressed ESCC. Moreover, univariate and multivariate Cox regression analyses showed that N stage, intraoperative hemorrhage volume, and SPCs are the autonomous risk factors impacting both OS and DFS of patients with locally advanced ESCC (Table 2).

# **3.4.** The correlation between SPCs and clinicopathological factors based on PNI levels

The correlation between distinct immune-nutritional statuses and the clinical-pathological characteristics related to SPCs is shown in Table 3. In the poor immunenutritional group, the ASA score was significantly different between the SPCs group and non-SPCs group (p=0.003). However, age (p=0.280), sex (p=0.287),



Figure 1. Kaplan-Meier survival curves for OS (A) and DFS (B) in locally advanced ESCC patients with SPCs and non-SPCs.

	Overall survival				Disease-free survival				
	Univariable analysis Multivariable analysis		alysis	Univariable and	alysis	Multivariable analysis			
Characteristics	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	
Age(years)									
≤65									
>65	1.322(0.937-1.865)	0.112			1.292(0.937-1.782)	0.119			
Sex									
Female									
Male	1.088(0.777–1.524)	0.624			0.996(0.726–1.365)	0.978			
BMI (kg/m <sup>2</sup> )									
≤18.5									
18.5–25	0.993(0.620–1.589)	0.977			1.094(0.693–1.727)	0.699			
≥25	1.166(0.644–2.112)	0.612			1.425(0.815–2.491)	0.214			
Comorbidities									
None									
Hypertension	0.766(0.489–1.198)	0.243			0.681(0.441–1.052)	0.083			
Diabetes	0.536(0.199–1.448)	0.219			0.563(0.231 - 1.370)	0.205			
Coronary neart disease	1.992(0.493-8.048)	0.334			1.469(0.364-5.927)	0.589			
LOW TISK Modium rick	1 154/0 621 2 145)	0 6 5 1	1 062(0 561 2 012)	0 950	1 100/0 627 1 060)	0 7 2 2			
High rick	1.134(0.021-2.143) 1.470(1.004-2.154)	0.031	1.003(0.301-2.013) 1.366(0.014-2.042)	0.032	1.109(0.027 - 1.900) 1.380(0.066 - 1.006)	0.725			
	1.470(1.004-2.134)	0.040	1.500(0.914-2.042)	0.120	1.569(0.900-1.990)	0.070			
	1 636(1 121-2 387)	0.011	1 232(0 810-1 876)	0 33	1 536(1 076-2 193)	0.018	1 241(0 851-1 809)	0 262	
Tumour location	1.050(1.121 2.507)	0.011	1.252(0.010 1.070)	0.55	1.556(1.676 2.175)	0.010	1.211(0.031 1.003)	0.202	
Proximal									
Mid	1.346(0.786-2.305)	0.279			1.637(0.960-2.790)	0.07			
Distal	1.198(0.669–2.147)	0.543			1.402(0.790-2.487)	0.248			
Histologic grade									
Gx/G1									
G2	1.089(0.792–1.497)	0.6			1.118(0.832–1.503)	0.459			
G3	1.221(0.753–1.978)	0.418			1.152(0.733–1.810)	0.54			
Tumour invasion									
T1									
T2	0.914(0.437–1.912)	0.812			0.981(0.488–1.972)	0.957			
13/14a	1.54/(0.815–2.938)	0.182			1.652(0.897-3.042)	0.107			
Lymph node metastasis									
NU N1	1 402/1 001 2 224)	<0.001	1 540/1 025 2 212)	0 0 2 0	1 407/0 076 2 029)	0.067	1 406/0 060 2 020)	0 072	
	1.492(1.001-2.224) 2.201(1.557-2.401)	< 0.001	1.540(1.025-2.512) 2.500(1.691, 2.742)	0.050	1.407(0.970-2.020)	0.007	1.400(0.909-2.059) 2.461(1.711, 2.540)	0.072 <0.001	
N3	2.301(1.557 - 5.401) 4.407(2.546 - 7.697)	<0.001	5 215(2 952_9 211)	<0.001	2.303(1.012-3.209)	<0.001	2.401(1.711-3.540) 4.743(2.584-7.744)	<0.001	
Neoadiuvant therapy	4.427 (2.340-7.077)	<0.001	5.215(2.952-9.211)	<0.001	5.557 (2.510-0.700)	<0.001	+./+J(2.J0+-/./++)	<0.001	
Yes									
No	1.374(0.976-1.936)	0.069			1.344(0.976-1.851)	0.07			
Surgical method									
McKeown									
lvor Lewis	0.682(0.413-1.126)	0.135			0.685(0.432-1.089)	0.11			
Lymphadenectomy									
Two-field									
Three-field	0.897(0.577–1.393)	0.627			0.875(0.574–1.335)	0.537			
Intraoperatve blood loss(ml)									
≤100									
100–200	1.245(0.902–1.717)	0.182	1.235(0.893–1.708)	0.202	1.159(0.857–1.568)	0.338	1.139(0.841–1.542)	0.401	
≥200	2.003(1.293–3.104)	0.002	2.236(1.423–3.514)	<0.001	2.101(1.416–3.118)	<0.001	2.304(1.534–3.461)	<0.001	
Adjuvant therapy									
NU Voc	0 696(0 500_0 052)	0 0 2 2	0 777(0 565_1 060)	0 1 2 1	0 616(0 450 0 826)	0.001	0 650/0 400_0 887\	0.006	
PNI	0.090(0.909-0.932)	0.023	(800.1-005-1.008)	0.121	0.010(0.+39-0.020)	0.001	0.009(0.490-0.00/)	0.000	
>47.1									
<47.1	0.913(0.655-1.273)	0.593			0.943(0.694-1.281)	0.709			
SPCs									
No									
Yes	1.639(1.193–2.250)	0.002	1.591(1.135–2.231)	0.007	1.585(1.179–2.130)	0.002	1.500(1.097–2.049)	0.011	

#### Table 2. Univariate and multivariate Cox analysis of clinicopathological factors for OS and DFS.

BMI (p=0.626), comorbidities (p=0.700), MUST (p=0.672), tumour location (p=0.385), histologic grade (p=0.515), tumour invasion (p=0.250), lymph node metastasis (p=0.617), neoadjuvant therapy (p=0.808), surgical method (p=0.249), lymphadenectomy

(p=0.302), intraoperative blood loss (p=0.778) and adjuvant therapy (p=0.997) were not significantly different between the SPCs group and non-SPCs group.

For the preserved immunenutritional group, the non-SPCs group had a higher proportion of male

Table 3. Correlations between SPCs and clinicopathological factors in the high and low PNI groups.

		PNI < 47.1		PNI ≥ 47.1			
		SPCs					
Characteristics	Yes (n=25)	No(n=84)	P value	Yes (n=77)	No( <i>n</i> = 256)	P value	
Age(years)			0.280			0.553	
≤65	16(64.0%)	63(75.0%)		64(83.1%)	205(80.1%)		
>65	9(36.0%)	21(25.0%)		13(16.9%)	51(19.9%)		
Sex			0.287			0.015	
Female	5(20.0%)	26(31.0%)		62(80.5%)	169(66.0%)		
Male	20(80.0%)	58(69.0%)		15(19.5%)	87(34.0%)		
BMI (kg/m²)		. ,	0.626	. ,		0.260	
≤18.5	2(8.0%)	12(14.3%)		5(6.5%)	29(11.3%)		
18.5–25	21(84.0%)	63(75.0%)		64(83.1%)	190(74.2%)		
≥25	2(8.0%)	9(10.7%)		8(10.4%)	37(14.5%)		
Comorbidities			0.700				
None	20(80.0%)	70(83.3%)		68(88,3%)	200(78.1%)	0.099	
Hypertension	5(20.0%)	14(16.7%)		4(5.2%)	42(16.4%)		
Diabetes	0(0.0%)	0(0.0%)		4(5.2%)	11(4.3%)		
Coronary heart disease	0(0.0%)	0(0.0%)		1(1.3%)	3(1.2%)		
MUST	0(0.070)	0(0.070)	0.672	1(1.570)	5(1.270)	0 248	
Low risk	18(72.0%)	67(79.8%)	0.072	56(72,7%)	206(80.5%)	0.240	
Medium risk	2(8.0%)	6(7.1%)		6(7.8%)	19(7.4%)		
High risk	5(20.0%)	11(13 1%)		15(10 5%)	31(12,1%)		
	5(20.070)	11(13.170)	0.003	13(17.570)	51(12.170)	<0.001	
	17(68.0%)	77(01 7%)	0.005	18(62 3%)	222(87 10%)	<0.001	
	9(22,00%)	7(91.770)		+0(02.3%) 20(27.7%)	223(07.170)		
Tumour location	0(32.0%)	7 (0.570)	0.205	29(37.7%)	33(12.9%)	0.060	
	1(4.00/)	E(C 00()	0.565	0(11 70/)	20/11 20/)	0.969	
Mid	1(4.0%)	5(0.0%)		9(11.7%)	29(11.5%)		
Nilu	20(00.0%)	22(22,2%) 24(29,6%)		40(39.7%)	137(01.3%)		
Uistalogia grada	4(10.0%)	24(20.0%)	0 5 1 5	22(20.0%)	70(27.5%)	0.225	
Histologic grade	12(40.00/)	21/26 00/)	0.515	24(44 20/)	00/24 00/)	0.325	
	12(48.0%)	31(30.9%)		34(44.2%)	89(34.8%)		
62	9(30.0%)	41(48.8%)		34(44.2%)	133(52.0%)		
G3	4(16.0%)	12(14.3%)	0.250	9(11.7%)	34(13.3%)	0 1 2 7	
	0(0,00())	7(0, 20()	0.250	2/2 (0/)	22/2 20/)	0.137	
	0(0.0%)	/(8.3%)		2(2.6%)	23(9.0%)		
12	3(12.0%)	14(16.7%)		13(16.9%)	49(19.1%)		
13/14a	22(88.0%)	63(75.0%)		62(80.5%)	184(71.9%)		
Lymph node metastasis			0.617		00(06.00()	0.465	
NO	10(40.0%)	26(31.0%)		27(35.1%)	93(36.3%)		
N1	6(24.0%)	31(36.9%)		22(28.6%)	89(34.8%)		
N2	7(28.0%)	23(27.4%)		24(31.2%)	58(22.7%)		
N3	2(8.0%)	4(4.8%)		4(5.2%)	16(6.3%)		
Neoadjuvant therapy			0.808			0.375	
Yes	5(20.0%)	15(17.9%)		16(20.8%)	42(16.4%)		
No	20(80.0%)	69(82.1%)		61(79.2%)	214(83.6%)		
Surgical method			0.249			0.218	
McKeown	24(96.0%)	74(88.1%)		66(85.7%)	232(90.6%)		
Ivor Lewis	1(4.0%)	10(11.9%)		11(14.3%)	24(9.4%)		
Lymphadenectomy			0.302			0.263	
Two-field	20(80.0%)	74(88.1%)		66(85.7%)	231(90.2%)		
Three-field	5(20.0%)	10(11.9%)		11(14.3%)	25(9.8%)		
Intraoperatve blood			0.778			0.413	
loss(ml)							
≤100	13(52.0%)	37(44.0%)		35(45.5%)	138(53.9%)		
100–200	9(36.0%)	36(42.9%)		29(37.7%)	84(32.8%)		
≥200	3(12.0%)	11(13.1%)		13(16.9%)	34(13.3%)		
Adjuvant therapy			0.997			0.954	
No	14(56.0%)	47(56.0%)		46(59.7%)	152(59.4%)		
Yes	11(44.0%)	37(44.0%)		31(40.3%)	104(40.6%)		

patients (p=0.015) and lower ASA score (p<0.001) than the SPCs group. However, age (p=0.553), BMI (p=0.260), comorbidities (p=0.099), MUST (p=0.248), tumour location (p=0.969), histologic grade (p=0.325), tumour invasion (p=0.137), lymph node metastasis (p=0.465), neoadjuvant therapy (p=0.375), surgical method (p=0.218), lymphadenectomy (p=0.263), intraoperatve blood loss (p=0.413) and adjuvant therapy (p=0.954) were not significantly different between the SPCs group and non-SPCs group.

# **3.5.** The relationship between SPCs and survival based on PNI levels

Kaplan-Meier survival analysis showed that SPCs significantly reduced 5-year OS (57.9% vs. 37.6%, p=0.008) and 5-year DFS (54.3% vs. 31.1%, p=0.011) of locally advanced ESCC patients with preserved immunenutritional status. However, SPCs did not significantly affect 5-year OS (50.9% vs. 46.5%, p=0.152) and 5-year DFS (48.6% vs. 36.3%, p=0.098) of patients with poor immune-nutritional status (Figure 2). Moreover, univariate and multivariate Cox regression analyses showed that N stage and postoperative severe complications were the independent risk factors for OS within the subset of locally advanced ESCC patients with preserved immune-nutritional status. Furthermore, the risk factors for DFS included N stage, intraoperative hemorrhage, and SPCs (Table 4).

# **3.6. Establishment of nomograms based on SPCs** *in the preserved Immune-nutritional group*

A prognostic model was developed by incorporating the independent risk factors identified in the multifactorial Cox regression analysis into a nomogram to assess the risk of OS and DFS in locally advanced ESCC patients with preserved immune-nutritional status (Figure 3). The calibration curve exhibited a remarkable congruence between the prognostic predictions based on the nomogram and the actual clinical outcomes for 3-year and 5-year OS among patients with preserved immune-nutritional status. The model demonstrated a comparable consistency with clinical reality in predicting 3-year and 5-year DFS (Figure 4).

### **3.7.** Risk staging for patients with preserved immunonutritional status

The X-Tile software was used for risk stratification of survival probabilities in locally advanced ESCC based on nomogram scoring. The patients were categorized into low-risk (<34 points), moderate-risk (34–67 points), and high-risk (>67 points) groups according to the optimal cut-off value for OS scoring (Figure S2). The 5-year OS rates for the low-risk, moderate-risk, and high-risk groups were 66.1%, 46.1%, and 10.5%, respectively (p<0.001). Similarly, the patients were classified into low-risk (<45 points), moderate-risk (45–96 points), and high-risk (>96 points) groups based on the optimal cut-off value for DFS scoring (Figure S3). The 5-year DFS rates for the low-risk, moderate-risk, and high-risk groups were 62.5%, 43%, and 5.5%, respectively (p<0.001) (Figure 5).



Figure 2. Kaplan–Meier survival curves for patients with SPCs and non-SPCs. OS (A) and DFS (B) in low-PNI; OS (C) and DFS (D) in high-PNI.

		Overall	survival		Disease-free survival				
	Univariable analysis		Multivariable analysis		Univariable analysis		Multivariable analysis		
Characteristics	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	HR(95%CI)	P-value	
Age(years)									
≤65									
>65	1.426(0.943–2.156)	0.093			1.370(0.931–2.018)	0.111			
Sex									
Female									
Male	1.019(0.685–1.515)	0.927			0.892(0.612–1.300)	0.552			
BMI (kg/m²)									
≤18.5									
18.5–25	1.003(0.572–1.758)	0.992			1.258(0.707–2.235)	0.435			
≥25	1.217(0.609–2.432)	0.578			1.795(0.916–3.515)	0.088			
Comorbidities									
None	0 (00/0 204 1 201)	0 1 0 0			0 ( )0 ( ) ) ( ) 1 075)	0.00			
Hypertension Disketse	0.088(0.394 - 1.201)	0.188			0.029(0.308 - 1.075)	0.09			
Diabeles	0.527(0.194 - 1.431)	0.209			0.5/0(0.233 - 1.392) 1 526(0.277 - 6.176)	0.217			
disease	2.072(0.511-6.400)	0.506			1.520(0.577-0.170)	0.555			
Low risk									
Medium rick	0 804(0 414_1 030)	0 777			0 822(0 400_1 688)	0 594			
High risk	1 451(0 935-2 252)	0.777			1334(0871-2044)	0.324			
ASA score	1.151(0.555 2.252)	0.007			1.55 1(0.67 1 2.011)	0.105			
1/11									
III/IV	1.593(1.030-2.463)	0.036	1.267(0.793-2.025)	0.322	1.524(1.010-2.299)	0.045	1.174(0.754–1.828)	0.477	
Tumour location	,								
Proximal									
Mid	1.320(0.735-2.367)	0.353			1.590(0.891-2.837)	0.117			
Distal	1.098(0.578-2.087)	0.776			1.320(0.704–2.474)	0.386			
Histologic grade									
Gx/G1									
G2	1.238(0.854–1.796)	0.26			1.189(0.842–1.681)	0.326			
G3	1.218(0.670–2.216)	0.518			1.164(0.675–2.008)	0.585			
Tumour invasion									
T1									
12	0.997(0.417–2.389)	0.995			1.087(0.483–2.445)	0.84			
13/14a	1.698(0.790-3.649)	0.175			1./00(0.831–3.480)	0.146			
Lymph node									
metastasis									
NU N1	1 575/0 005 2 510)	0.059	1 504/0 006 2 552)	0.050	1 562/1 010 2 200)	0.041	1 515/0 002 2 225)	0.060	
ND ND	2 465(1 556_3 006)	0.038 <0.001	7.394(0.990-2.332) 2.466(1.555_2.011)	<0.032	2 426(1 580 - 2.396)	0.041 <0.001	1.515(0.965-2.555) 2.468(1.607-3.700)	<0.000	
N3	5 534(2 967–10 322)	< 0.001	5 978(3 186-11 218)	< 0.001	5 369(2 923-9 862)	< 0.001	5 450(2 928–10 145)	< 0.001	
Neoadiuvant	5.554(2.567 10.522)	<0.001	5.570(5.100 11.210)	<0.001	5.507(2.525 5.002)	<0.001	5.450(2.520 10.145)	<0.001	
therapy									
Yes									
No	0.826(0.522-1.307)	0.414			0.997(0.661-1.504)	0.988			
Surgical method									
McKeown									
Ivor Lewis	0.806(0.463-1.405)	0.447			0.849(0.512-1.408)	0.526			
Lymphadenectomy									
Two-field									
Three-field	0.859(0.508–1.454)	0.572			0.927(0.564–1.524)	0.765			
Intraoperatve									
blood loss(ml)									
≤ IUU 100, 200	1 200/0 050 2 015	0.002			1 220/0 0/2 1 752	0 252	1 1 ( ( ) 0 1 ( ) 1 ( ( )	0 401	
100-200	1.390(0.959-2.015)	0.082			1.229(0.863-1.750)	0.253	1.105(0.816-1.663)	0.401	
≥200 Adiuwant therem:	1.030(0.950–2./95)	0.076			1.813(1.131-2.907)	0.013	1.915(1.177-3.114)	0.090	
Yes	0 774(0 538_1 114)	0 167			0 688(0 480_0 060)	0.032	0 772(0 545_1 002)	0 144	
SPCs	יייי), אוווי-טכניטאדי	0.107			0.000(0.409-0.909)	0.032	J.772(U.JHJ-1.U72)	0.144	
No									
Yes	1.636(1.133-2.364)	0.009	1.653(1.111-2.460)	0.013	1.553(1.099-2.193)	0.013	1.462(1.009-2.119)	0.045	
			2		(				

Table 4. Univariate and multivariate analysis of clinicopathological factors for OS and in high-PNI.

### 4. Discussion

This is the first study to elucidate the impact of SPCs on the long-term prognosis of patients with locally advanced ESCC after MIE based on preoperative immunonutritional status. Results showed that OS and DFS rates were significantly lower in the SPCs group than in the non-SPCs group for patients with preserved immunonutritional status. Furthermore,



Figure 3. Nomogram for predicting OS (A) and DFS (B) in high-PNI.

multifactorial regression analysis showed that SPCs are independent risk factors for OS and DFS. However, SPCs did not significantly affect the prognosis of patients with poor immunonutritional status.

Notably, there is controversy surrounding the impact of post-esophagectomy complications on the long-term survival of patients. Some studies have shown that patients who experience postoperative complications after esophageal cancer resection exhibit a poorer prognosis than those without such complications [7,23,24]. However, other reports have suggested that postoperative complications are not correlated with long-term survival rates after esophageal cancer resection [25,26]. In this study, SPCs significantly affected OS and DFS of patients with locally advanced ESCC after MIE. Nonetheless, the precise mechanisms by which SPCs affect the prognosis of esophageal cancer patients are unclear. Notably, several factors may be involved in this phenomenon. For example, Hirai et al. showed that surgical trauma induces excessive surgical stress, and the ensuing complications trigger a storm of inflammatory cytokine release during the perioperative period, increasing susceptibility to tumour metastasis, thus resulting in poor prognosis [27]. Residual cancer cells adhere to endothelial cells within blood vessels in the early postoperative phase when inflammatory cytokines are present, potentially elevating the chances of cancer metastasis and recurrence [28]. SPCs may lead to an adverse prognosis by increasing the likelihood of cancer metastasis and recurrence through the release of inflammatory cytokines, which exacerbate inflammation.

In this study, anastomotic leakage significantly affected locally advanced ESCC patients who have



Figure 4. Calibration curves for 3-and 5-year OS and DFS based on nomogram in high-PNI.



Figure 5. OS (A) and DFS (B) survival curves for low, intermediate, and high-risk patients stratified by nomogram score.

undergone MIE. Besides, previous studies showed that anastomotic leakage significantly affects the long-term survival of ESCC patients [29,30]. Anastomotic leakage is common after esophagectomy, and its occurrence is associated with an increased perioperative mortality rate. The postoperative onset of anastomotic leakage leads to the seepage of digestive fluids, causing local inflammation in milder cases, and may culminate in serious complications in severe cases, such as mediastinal abscess, empyema, and pneumothorax, thereby instigating a systemic inflammatory response. These findings indicate that SPCs may impact prognosis through a postoperative systemic inflammatory response. Moreover, studies have shown that inflammation is involved in cancer initiation and progression [31].

Meanwhile, postoperative pulmonary infections are prevalent after esophageal cancer radical surgery and are significantly related to patient prognosis. Studies have shown that various cytokines, such as IL-6, IL-8,

and TNF-a, are highly expressed in bronchial epithelial cells. Notably, the occurrence of postoperative pulmonary infections is concomitant with the release of these inflammatory mediators. Tomohiko Nishi et al. showed that the upregulation of IL-8 and its receptor CXCR-2 is correlated with the progression and unfavourable prognosis of patients with ESCC post-esophagectomy [32]. Masayuki Yoneda et al. also indicated that IL-6 expression can mediate the invasion and metastasis of esophageal tumours, thereby promoting cancer development [33].

A diminished immune-nutritional status increases the risk of postoperative complications and is correlated with poorer postoperative survival [34]. In this study, OS and DFS were lower in the SPCs group than in the non-SPCs group for patients with favourable immunonutritional status. However, SPCs did not significantly affect the prognosis of patients with poor immunonutritional status. This may be due to PNI, which consists of serum albumin and lymphocyte counts, is associated with the prognosis of various types of cancer [16]. Some studies have reported that a range of inflammatory factors can cause lymphocytopenia, which promotes abnormal growth of tumour cells [35,36]. At the same time, serum albumin levels reflect the body's nutrient reserves and reveal the severity of inflammation [37]. Therefore, low PNI reflects the state of immune deficiency and malnutrition of the patients. SPCs in patients will produce a large number of inflammatory factors, further reducing serum albumin and lymphocyte levels, thus inhibiting the anti-tumour effect. What's more, Satoru Okada et al. showed that SPCs may impact prognosis after lung cancer surgery, particularly within the subset of patients with a well-preserved immunonutritional status [38]. Therefore, perioperative care is crucial for preventing SPCs in patients with poor immune-nutritional status and those with preserved immunonutritional status.

Clinical prognostic models have been widely used to evaluate the prognosis of various cancers, enabling personalized and precise predictions of patient-specific target outcome events. Unlike traditional staging, nomograms provide enhanced precision and are more easily understood by patients, thus aiding in clinical decision-making. In this study, the locally advanced ESCC patients with preserved immune-nutritional status were classified into low, intermediate, and high-risk groups based on the nomogram-derived scores for predicting OS and DFS. Notably, mortality and recurrence rates were significantly different among the three categories. These results indicate that nomogram scores can be used for risk stratification to provide a dependable prognostic system, representing a valuable supplement to the conventional TNM staging system. Clinicians should consider individualized close monitoring and effective adjuvant therapy for patients when the score indicates an increased risk of mortality or recurrence in ESCC patients.

Although this study had a large sample size, standardized surgical procedures, and standardized perioperative management, it has some limitations. First, this was a single-centre retrospective study that included a population of patients with ESCC from 2011 to 2018. so there was selection bias and chronology bias. At the same time, this study comes from a high-volume centre, which may limit the popularization and application of the nomogram. In addition, only ESCC patients were included in this study. Due to the differences in histology and clinical prognosis between ESCC and esophageal adenocarcinoma, the conclusions of this study may not be applicable to patients with esophageal adenocarcinoma. Moreover, there was heterogeneity in the surgical modalities included in this study, including Ivor-Lewis and McKeown esophagectomy, which may have contributed to relative performance bias. Currently, neoadjuvant therapy is recommended for patients with stage II/III ESCC. In our study, about 17.6% of the participants were on neoadjuvant therapy. Therefore, this may be a limitation in generalizing these results to other series. Finally, external validation is needed to assess the stability and applicability of the model since the predictive efficacy of nomograms can fluctuate with application contexts and demographics.

### 5. Conclusion

SPCs significantly reduce OS and DFS in ESCC patients based on PNI, especially for patients with preserved immunonutritional status. However, SPCs do not significantly affect the long-term survival of patients with poor immune-nutritional status. In this study, the developed nomogram exhibited good predictive ability. Moreover, the innovative staging system could effectively identify mortality and relapse risk in patients. Therefore, high-risk individuals among patients with advanced local ESCC with favourable immunonutritional status require individualized monitoring and proactive therapeutic interventions.

#### **Authors contributions**

Chao Chen (Co-first authors): Conceptualization, Methodology, Investigation, Formal Analysis, Writing-Original Draft; Shao-Jun Xu (Co-first authors): Methodology, Investigation, Data Curation, Formal Analysis; Zhi-Fan Zhang: Data Curation, Writing-Original Draft; Cheng-Xiong You: Visualization, Investigation; Rui-Qin Chen: Resources, Supervision; Yun-Fan Luo: Validation, Writing - Review & Editing. Shu-Chen Chen (Corresponding Author): Conceptualization, Funding Acquisition, Resources, Supervision, Writing - Review & Editing. All authors agree to be accountable for all aspects of the work.

#### **Disclosure statement**

No potential conflict of interest was reported by the authors.

### Funding

This study was supported by grants from the Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University (No. 0713304); the Natural Science Foundation in Fujian Province (No. 2020J011004); the Fujian provincial health technology project (No. 2020CXA028); the cohort study of the School of Public Health, Fujian Medical University (No. 2021HX003); the Joint Funds for the innovation of science and Technology, Fujian province (No. 2020Y9076); and the National Nature Science Foundation of China (No. 82273415).

#### Data availability statement

The data that support the findings of this study are available from the corresponding author, Shu-Chen Chen, upon reasonable request.

#### References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
- [2] Wang K, Johnson A, Ali SM, et al. Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences. Oncologist. 2015;20(10):1132– 1139. doi: 10.1634/theoncologist.2015-0156.
- [3] Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232(2):225–232. doi: 10.1097/00000658-200008000-00013.
- [4] Low DE, Bodnar A. Update on clinical impact, documentation, and management of complications associated with esophagectomy. Thorac Surg Clin. 2013;23(4): 535–550. doi: 10.1016/j.thorsurg.2013.07.003.
- [5] Triantafyllou T, Wijnhoven BPL. Current status of esophageal cancer treatment. Chin J Cancer Res. 2020;32(3):271– 286. doi: 10.21147/j.issn.1000-9604.2020.03.01.
- [6] Raymond DP, Seder CW, Wright CD, et al. Predictors of major morbidity or mortality after resection for esophageal cancer: a society of thoracic surgeons general thoracic surgery database risk adjustment model. Ann

Thorac Surg. 2016;102(1):207–214. doi: 10.1016/j.athoracsur.2016.04.055.

- [7] Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198(1):42–50. doi: 10.1016/j.jamcollsurg.2003.08.007.
- [8] Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg. 2020;271(4):693–700. doi: 10.1097/SLA.000000000002985.
- [9] Mariette C, De Botton ML, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol. 2012;19(7):2128–2134. doi: 10.1245/s10434-012-2225-6.
- [10] Migita K, Takayama T, Saeki K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol. 2013;20(8):2647–2654. doi: 10.1245/s10434-013-2926-5.
- [11] Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028– 1030. doi: 10.1038/sj.bjc.6601242.
- [12] Lee SC, Huh JW, Lee WY, et al. Prognostic value of serum inflammatory markers in colorectal cancer. Int J Colorectal Dis. 2020;35(7):1211–1219. doi: 10.1007/ s00384-020-03591-1.
- [13] Wang F, He W, Jiang C, et al. Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer. BMC Cancer. 2018;18(1):1102. doi: 10.1186/s12885-018-4842-3.
- [14] Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci. 2021;22(15):8002. doi: 10.3390/ijms22158002.
- [15] Xie H, Wei L, Liu M, et al. Neutrophil-albumin ratio as a biomarker for postoperative complications and long-term prognosis in patients with colorectal cancer undergoing surgical treatment. Front Nutr. 2022;9:976216. doi: 10.3389/fnut.2022.976216.
- [16] Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139(1):160–167. doi: 10.1016/0002-9610 (80)90246-9.
- [17] Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106(8):1439–1445. doi: 10.1038/ bjc.2012.92.
- [18] Mohri Y, Inoue Y, Tanaka K, et al. Prognostic nutritional index predicts postoperative outcome in colorectal cancer. World J Surg. 2013;37(11):2688–2692. doi: 10.1007/ s00268-013-2156-9.
- [19] Nakatani M, Migita K, Matsumoto S, et al. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy. Dis Esophagus. 2017;30(8):1–7. doi: 10.1093/dote/dox020.
- [20] Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–373. doi: 10.1053/j.gastro.2017.08.023.

- [21] Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8(1):100789. doi: 10.1016/j.esmoop.2023. 100789.
- [22] Zhu H, Ma X, Ye T, et al. Esophageal cancer in China: practice and research in the new era. Int J Cancer. 2023;152(9):1741–1751. doi: 10.1002/ijc.34301.
- [23] Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34(2):277–284. doi: 10.1007/s00268-009-0331-9.
- [24] Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250(5):798–807. doi: 10.1097/SLA.0b013e3181bdd5a8.
- [25] Ferri LE, Law S, Wong KH, et al. The influence of technical complications on postoperative outcome and survival after esophagectomy. Ann Surg Oncol. 2006;13(4):557–564. doi: 10.1245/ASO.2006.04.040.
- [26] Ancona E, Cagol M, Epifani M, et al. Surgical complications do not affect longterm survival after esophagectomy for carcinoma of the thoracic esophagus and cardia. J Am Coll Surg. 2006;203(5):661–669. doi: 10.1016/j. jamcollsurg.2006.07.017.
- [27] Hirai T, Matsumoto H, Kubota H, et al. Regulating surgical oncotaxis to improve the outcomes in cancer patients. Surg Today. 2014;44(5):804–811. doi: 10.1007/ s00595-013-0627-0.
- [28] McDonald B, Spicer J, Giannais B, et al. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer. 2009;125(6):1298–1305. doi: 10.1002/ijc.24409.
- [29] Markar S, Gronnier C, Duhamel A, et al. The impact of severe anastomotic leak on long-term survival and can-

cer recurrence after surgical resection for esophageal malignancy. Ann Surg. 2015;262(6):972–980. doi: 10.1097/SLA.000000000001011.

- [30] Ferguson MK, Celauro AD, Prachand V. Prediction of major pulmonary complications after esophagectomy. Ann Thorac Surg. 2011;91(5):1494–1501. discussion 1500-1491. doi: 10.1016/j.athoracsur.2010.12.036.
- [31] Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211–217. doi: 10.1016/j.ccr.2005.02.013.
- [32] Nishi T, Takeuchi H, Matsuda S, et al. CXCR2 expression and postoperative complications affect long-term survival in patients with esophageal cancer. World J Surg Oncol. 2015;13(1):232. doi: 10.1186/s12957-015-0658-7.
- [33] Yoneda M, Fujiwara H, Furutani A, et al. Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. Anticancer Res. 2013;33(6): 2699–2705.
- [34] Okamura A, Yamashita K, Kozuki R, et al. Inflammatory response and recurrence after minimally invasive esophagectomy. Langenbecks Arch Surg. 2019;404(6):761– 769. doi: 10.1007/s00423-019-01818-6.
- [35] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi: 10.1038/nature07205.
- [36] Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39– 51. doi: 10.1016/j.cell.2010.03.014.
- [37] McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–226. doi: 10.1097/ MCO.0b013e32832a7902.
- [38] Okada S, Shimada J, Kato D, et al. Long-term prognostic impact of severe postoperative complications after lung cancer surgery. Ann Surg Oncol. 2019;26(1):230– 237. doi: 10.1245/s10434-018-7061-x.